A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
- First Posted Date
- 2012-05-28
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 878
- Registration Number
- NCT01606761
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1670
- Registration Number
- NCT01604343
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
- First Posted Date
- 2012-05-16
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT01599949
A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 96
- Registration Number
- NCT01597739
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Phase 3
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 313
- Registration Number
- NCT01591122
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult Men
Phase 1
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT01588782
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
- First Posted Date
- 2012-04-23
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 121
- Registration Number
- NCT01582815
A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men
Phase 1
Completed
- Conditions
- Pharmacology
- First Posted Date
- 2012-04-11
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT01575587
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 1
Completed
- Conditions
- Relapsed or Refractory Hodgkin Lymphoma
- Interventions
- Drug: Phase 1, Cohort 1Drug: Phase 1, Cohort 2Drug: Phase 1, Cohort 3Drug: Phase 1, Cohort 4Drug: Phase 2
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 21
- Registration Number
- NCT01572519
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
Phase 1
Completed
- Conditions
- CD20-positive B-cell Non-Hodgkin Lymphoma
- Interventions
- Drug: Part 1, Cohort 1Drug: Part 1, Cohort 2Drug: Part 1, Cohort 3Drug: Part 2, Cohort 1Drug: Part 2, Cohort 2
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT01569750
© Copyright 2025. All Rights Reserved by MedPath